The largest database of trusted experimental protocols

14 protocols using h1152

1

Cell Cycle Analysis of L1210 FUCCI Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Experiments were carried out using mAG-hGeminin–expressing L1210 FUCCI cell line, which was generated in a previous study (5 (link)) and originated from ATCC (catalog no. CCL-219). However, the RO-3306 treatment experiments were carried out using the parental L1210 cells, as the FUCCI cells displayed higher RO-3306 toxicity than the parental cells. Cells were grown in RPMI media (containing 11 mM glucose, 2 mM l-glutamine, 10% FBS, 1 mM sodium pyruvate, 20 mM Hepes, and antibiotic/antimycotic) at 37 °C in 5% CO2 and 21% O2 atmosphere. Cells tested negative for mycoplasma. Barasertib (also known as AZD1152-HQPA; Cayman Chemical; catalog no. 11602), H-1152 (Sigma-Aldrich; catalog no. 555550), and RO-3306 (Cayman Chemical; catalog no. 15149) were dissolved in DMSO. The chemical concentrations used were selected based on cell cycle phenotypes observed in control experiments.
+ Open protocol
+ Expand
2

Transient Expression in HEK293 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HEK (human embryonic kidney) 293 cells were maintained in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% (v/v) fetal bovine serum and 100 units/ml penicillin/100 µg/ml streptomycin at 37°C in 5% CO2 atmosphere. Transient expression in HEK293 cells was performed by transfecting the plasmids using FuGENE6 (Roche) or polyethylenimine (Sigma) according to the manufacturer’s instructions. LRRK2-IN-1 was provided by Professor Dario Alessi (University of Dundee). Sunitinib and H-1152 were purchased from Sigma and Calbiochem, respectively. LRRK2-IN-1 and Sunitinib were dissolved in dimethyl sulfoxide (DMSO). H-1152 was dissolved in sterilized distilled water (SDW). Thirty-six hours after transfection, cells were treated with inhibitors or an equivalent volume of solvents (DMSO or SDW). The final concentrations of solvents were 0.1% (v/v) for DMSO and 1% (v/v) for SDW.
+ Open protocol
+ Expand
3

Apoptotic Body Isolation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lymphoma cells were plated at 2×105 cells per well of 12-well tissue culture plates, then on the next day, they were treated with 10 µM H1152 (R&D Systems) for 4 h, 10 µM ABT199 (Selleckchem) plus 10 ng/ml Chx (Sigma-Aldrich) for 1 h, or a combination of H1152 (4 h) plus ABT199 and Chx (1 h). Cell cultures were placed on ice and conditioned medium containing apoptotic bodies was collected in ice-cold centrifuge tubes, then ice-cold PBS was added, cells were scraped and transferred to the corresponding ice-cold centrifuge tubes. After centrifugation at 2000 g for 5 min at 4°C, supernatants were discarded and pellets were washed in 1 ml of PBS, followed by another centrifugation at 2000 g for 5 min at 4°C. Supernatants were discarded and pellets were resuspended in 200-250 µl of sodium dodecyl sulphate (SDS) lysis buffer [1% (w/v) SDS, 50 mM Tris-HCl pH 7.5], which was transferred to QIAshredder tubes (QIAGEN) and centrifuged for 1 min at 20,000 g. The flow-through was transferred to fresh Eppendorf tubes and frozen (either rapid freezing or overnight freezing at −80°C). The lysates were thawed on ice before being centrifuged at 20,000 g for 15 min at 4 C. The supernatants were transferred to new microfuge tubes, the protein concentration determined, and samples stored at −20°C.
+ Open protocol
+ Expand
4

IEC Spheroid Formation and Passage

Check if the same lab product or an alternative is used in the 5 most similar protocols
IEC spheroids were generated as described [25 (link)]. Spheroid-forming numbers were determined by counting numbers of spheroids per well on Day 3 of the 6th passage in the presence and absence of Y27632 (10 μM), H1152 (0.31 μM) and 4-hydroxy tamoxifen (4-OHT) (Sigma-Aldrich, St. Louis, MO, USA, 1 μM). Spheroid passage numbers were determined by counting numbers of spheroids per well on Day 3 of the 7th passage in the continued presence of inhibitors. Spheroids with diameters ≥100 μM were counted.
+ Open protocol
+ Expand
5

CASR-Mediated YAP1 Nuclear Translocation

Check if the same lab product or an alternative is used in the 5 most similar protocols
To investigate the potential role of downstream effectors RhoA/ROCK in CASR-mediated nuclear translocation of YAP1, 48 h after transfection, serum-starved CASR-HEK293A cells were pre-treated for 1 h with either 10 μM Y-27632 or 1 μM H-1152 (both from Sigma–Aldrich) in PSS supplemented with 0.1% BSA and 1.5 mM [Ca2+]o. Subsequently, the cells were stimulated for 1 h with increasing concentrations of R568 (as described above) in the presence or absence of the Rho-kinase inhibitors. Untreated cells (NT) were used as controls.
+ Open protocol
+ Expand
6

Actin and ROCK Perturbation Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Actin perturbations were carried out using Lat A (Invitrogen); at 20μM for 15 minutes in case of anisotropy measurements, and at 1 μM for 1 hour in case of FCS. ROCK perturbations were carried out using 10μM H1152 (Sigma) for 1 hour. Imaging was carried out in the presence of the drug. All drug treatments were carried out in M1 buffer (150mM NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2 and 20mM HEPES - pH 6.9) containing 1mg/ml BSA and 2mg/ml glucose at 23°C BOD incubator for the indicated time periods.
+ Open protocol
+ Expand
7

Generation of Hematopoietic Stem Cells from iPSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patient-specific iPSCs were differentiated into hematopoietic stem cells (HSCs) under defined, serum-free and feeder-free conditions as previously reported.20 (link) Briefly, TrypLE (Invitrogen)-dissociated iPSCs were seeded onto 6-well plates that were precoated with 3 mg cm−2 human plasma fibronectin (Invitrogen) in mTeSR1 supplemented with an inhibitor of Rho-associated kinase (H1152, Sigma). After 1 day, mTeSR1 was replaced with a hematopoietic commitment medium containing Iscove's modified Dulbecco's medium (Invitrogen) supplemented with 1 × HIT (Stem Cell Technologies), 450 μM monothioglycerol (Sigma), 50 ng ml−1 recombinant human BMP4 (R&D Systems), 50 ng ml−1 recombinant human vascular endothelial growth factor (Invitrogen), 0.1 mM NEAA (Invitrogen) and 2 mM L-glutamine (Invitrogen). After 6 days, the medium was changed to a hematopoietic maturation medium consisting of Iscove's modified Dulbecco's medium (Invitrogen) supplemented with 5 U ml−1 heparin (Sigma), 25 ng ml−1 thrombopoietin (Invitrogen), 25 ng ml−1 human recombinant stem cell factor (Invitrogen), 25 ng ml−1 human recombinant FLT3L (Peprotech, Rocky Hill, NJ, USA), 10 ng ml−1 interleukin-3 (Invitrogen) and 10 ng ml−1 interleukin-6 (Invitrogen). The cells were incubated under hypoxic conditions (5% O2 balanced with nitrogen).
+ Open protocol
+ Expand
8

Migration Assay with Cell Signaling Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
All tissue culture, inhibitors and general reagents were purchased from Sigma-Aldrich (Poole, UK), except AA (MP Biomedicals, London, UK), which was emulsified at 10 mg ml−1 in methyl-β-cyclodextrin. Hygromycin B and foetal calf serum (FCS) were from PAA Laboratories (Yeovil, UK). Matrigel and 8 μm FluoroBlok cell-culture inserts were from BD Biosciences (Oxford, UK).
Antibodies were from Cell Signalling Technology (New England BioLabs (UK) Ltd, Hitchin, UK) except GAPDH, which was from Abcam (Cambridge, UK). Y-27632, Rac-1 inhibitor, GM6001, H1152 and blebbistatin were from Merck Biosciences (Nottingham, UK). All On-Target Plus Smartpool siRNAs were from Dharmacon, Thermo Fisher Scientific (Fermentas GmbH, St Leon, Germany). Protease and phosphatase inhibitor cocktail were purchased from Roche (Sussex, UK).
+ Open protocol
+ Expand
9

Inhibition of CD8+ T-cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
For some experiments, prior to co-culture with BEC, CD8+ T cells were treated with molecular inhibitors for 30 min (1 μM Wortmannin [Merck, Cat No. W1628], 5 nM H-1152 [Merck, Cat No. 555550] or 5 μM cytochalasin D [Merck, Cat No. C2618]). Inhibitors were solubilised to stock concentrations such that the DMSO content of inhibitors prepared at working concentrations, would be no more than 0.1%. Concentrations of all treatments and relevant vehicle controls were maintained throughout the co-culture duration.
+ Open protocol
+ Expand
10

Dissociated Spiral Ganglion and Dorsal Root Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols
Spiral and dorsal root ganglia dissociated cultures were prepared from
P1–5 rat pups and maintained as previously described [4 (link), 18 (link)]. The cell suspension was
plated in glass cylinders on polymer films. Experimental manipulation began 3–6 h
later to allow for cell adhesion. H1152 (EMD Millipore, Billerica, MA), Y27632 (EMD
Millipore), Rho Activator II (Cytoskeleton, Denver, CO, CN03), C3 transferase
(Cytoskeleton, CT04), Ruthenium red (Tocris Bioscience, Bristol, UK), gentamicin (Sigma),
SKF96365 (EMD Millipore), cpt-cAMP (Sigma), 8-Br-cGMP (Sigma), GsTMx-4 (Peptides
International, Louisville, KY) or the appropriate control carrier were added to the
indicated cultures. Dissociated spiral ganglion Schwann cells (SGSCs) cultures were
prepared as previously described [19 (link), 20 (link)]. Briefly, dissociated SG cultures were plated on
laminin-coated polymer films and maintained Dulbecco’s Modified Eagle Medium (Life
Technologies) supplemented with N2 (Life Technologies) and insulin (10 µg/ml, Life
Technologies) in the absence of neurotrophic factors or serum for at least 96 h prior to
experimental manipulation. In the absence of neurotrophic support, nearly all of the SGNs
in the culture die within 48 h. By 96 h, >95% of cells were S100-positive
SGSCs [19 (link), 20 (link)].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!